Interviews

David G. Miller, RPh, discusses the roles of the FDA and state boards of pharmacy in regulating compounding pharmacies.

Specialty Pharmacy Times contributor Quintin Jessee discusses why he chose a career in specialty pharmacy and the new opportunities that are emerging in this industry.

A patient with unyielding pain for a decade learns how to manage her pain at the Mayo Clinic's Pain Rehabilitation Center.

Sherilyn Driscoll, MD, a pediatrics physiatrist at the Mayo Clinic, discusses how treatment of chronic pain in children has changed.

Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.

The Formation of SPAARx

By

Bill Sullivan of the Specialty Pharmacy Association of America describes the growth of the specialty pharmacy industry and the factors that prompted the formation of SPAARx.

Hyponatremia Explained Clearly

By

Clinical and exam preparation instructor Roger Seheult, MD, provides the first part of a 4-part course explaining hyponatremia.

Carrie Hurwitz, MBA, director, corporate strategy and business development at McKesson, explains why pharmacists may be the health care providers best positioned to recruit patients into clinical trials.

Einodshofer of Walgreens explains that it can be difficult to convince oncologists with hospital-owned oncology practices to send patients to alternative treatment sites.

Some pharmaceutical manufacturers choose a limited distribution model for their specialty product so that they can ensure all standards of care and reporting associated with that therapy are upheld, noted Duane Barnes, senior vice president, consumer delivery, Prime Therapeutics, at the 2013 Armada Specialty Pharmacy Summit.

Prime Therapeutics projects that by 2017, the cost of specialty pharmaceuticals will be half the cost of all pharmacy claims. Therefore, noted Duane Barnes, senior vice president, consumer delivery at Prime Therapeutics, it is important for a PBM to align its medical and pharmacy policies.

Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.

Bill Sullivan, executive director of SPAARx, describes how his organization's definition of "specialty pharmacy" compares with other entities' definitions.

Philip R. Schauer, MD, discusses the need for accountable care organizations to recognize obesity as a disease and offer treatment for it.

How Does An ACO Work?

By

Jennifer Athay-Adams, PharmD, discusses how the payment model of accountable care organizations (ACOs) differs from that of traditional HMOs.

Debbie Stern of Rxperts discusses the findings from the EMD Serono Specialty Digest, 9th Edition, and the use of specialty drug tiers by payers.

Pharmacy accreditation is starting to gain some recognition, noted Quintin Jessee, RPh, DPh, D2 Pharma Consulting in this video shot at the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

Michael Einodshofer, director, utilization management, Walgreens, describes how contractual methodologies and cost differences across various sites of service can influence how a specialty drug is reimbursed under the medical benefit.